GRI Bio, Inc. (GRI) NASDAQ
2.37
-0.06(-2.47%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.37
-0.06(-2.47%)
Currency In USD
Address
2223 Avenida de la Playa
La Jolla, CA 92037
United States of America (the)
Phone
619 400 1170
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3
First IPO Date
April 24, 2023
| Name | Title | Pay | Year Born |
| W. Marc Hertz | Co-Founder, Chief Executive Officer, President & Director | 617,224 | 1970 |
| Vipin Kumar | Co-Founder & Chief Scientific Officer | 419,420 | 1959 |
| Albert Agro | Co-Founder & Chief Medical Officer | 461,099 | 1964 |
| Leanne Kelly | Chief Financial Officer & Corporate Secretary | 469,420 | 1977 |
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.